Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to ...

Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...

In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of ...

Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.’s HPV vaccine ...

Amylyx Pharmaceuticals is helping patients follow the clues to uncover the mystery of rare weight-loss surgery complication post-bariatric hypoglycemia (PBH) with the launch of a new patient education ...

Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a ...

Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. | Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. Merck briefly posted—and then quickly ...

A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses. | A Daiichi Sankyo quarterly report that ...

Regeneron’s cut from the Dupixent sales boom was $2.11 billion in the quarter, which topped analysts’ consensus by $358 ...

Amgen, LeBron James and world’s top-subscribed YouTuber MrBeast may sound like a Mad Lib of unrelated influences, but the ...

The FDA has rebuked Viatris for a direct-to-consumer (DTC) video that allegedly misled viewers about a cystic fibrosis ...

Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the Illinois drugmaker's hopes that the duo could replace aging immunology su | ...